The effect of FK778 on the progression of chronic allograft nephropathy in a rat model

Transplantation

Volumn 83, Issue 6, 2007, Pages 741-746

  Lutz, Jens ^a   Huang, Hai ^a   Deng, Meihong ^a   Wagner, Bettina ^a   Roos, Marcel ^a   Schmaderer, Christoph ^a   Strobl, Matthias ^a   Heemann, Uwe ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chronic allograft nephropathy; FK778; Rat

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; IMMUNOHISTOCHEMISTRY; KIDNEY TRANSPLANTATION; LEWIS RAT; MALE; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; TREATMENT DURATION;

ALKYNES; ANIMALS; CREATININE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; KIDNEY; KIDNEY TRANSPLANTATION; MALE; NITRILES; PROTEINURIA; PROTO-ONCOGENE PROTEINS C-SIS; RATS; RATS, INBRED F344; RATS, INBRED LEW; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HOMOLOGOUS;

EID: 34147139494     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000255558.02582.ce     Document Type: Article

References (38)

1. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59: 313.
2. Fawcett J, Johnson DW. FK778: a powerful immunosuppressive, but will it really be good for you? Transplantation 2004; 78: 7.
3. Williamson RA, Yea CM, Robson PA, et al. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem 1995; 270: 22467.
4. Davis JP, Cain GA, Pitts WJ, et al. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 1996; 35: 1270.
5. Elder RT, Xu X, Williams JW, et al. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol 1997; 159: 22.
6. Siemasko K, Chong AS, Jack HM, et al. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 1998; 160: 1581.
7. Vanrenterghem Y, van Hooff JP, Klinger M, et al. The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation 2004; 78: 9.
8. Racusen LC, Solez, K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
9. Pan F, Ebbs A, Wynn C, et al. FK778, a powerful new immunosuppressant, effectively reduces functional and histologic changes of chronic rejection in rat renal allografts. Transplantation 2003; 75: 1110.
10. Crews GM, Erickson L, Pan F, et al. Down-regulation of TGF-beta and VCAM-1 is associated with successful treatment of chronic rejection in rats. Transplant Proc 2005; 37: 1926.
11. Savikko J, Von Willebrand E, Hayry P. Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection. Transplantation 2003; 76: 455.
12. Deuse T, Schrepfer S, Koch-Nolte F, et al. FK778 and tacrolimus prevent the development of obliterative airway disease after heterotopic rat tracheal transplantation. J Heart Lung Transplant 2005; 24: 1844.
13. Schrepfer S, Deuse T, Schafer H, Reichenspurner H. FK778, a novel immunosuppressive agent, reduces early adhesion molecule upregulation and prolongs cardiac allograft survival. Transpl Int 2005; 18: 215.
14. Lindner JK, Zantl N. Synergism of the malononitrilamides 279 and 715 with cyclosporine A in the induction of long-term cardiac allograft survival. Transpl Int 1998; 11: S303.
15. Diamond JR, Tilney NL, Frye J, et al. Progressive albuminuria and glomerulosclerosis in a rat model of chronic renal allograft rejection. Transplantation 1992; 54: 710.
16. HancockWH,WhitleyWD,Tullius SG, et al. Cytokines, adhesion molecules, and the pathogenesis of chronic rejection of rat renal allografts. Transplantation 1993; 56: 643.
17. Nadeau KC, Azuma H, Tilney NL. Sequential cytokine expression in renal allografts in rats immunosuppressed with maintenance cyclosporine or mycophenolate mofetil. Transplantation 1996; 62: 1363.
18. Bilolo KK, Ouyang J, Wang X, et al. Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat. Transplantation 2003; 75: 1881.
19. Vu MD, Qi S, Wang X, et al. Combination therapy of malononitrilamide FK778 with tacrolimus on cell proliferation assays and in rats receiving renal allografts. Transplantation 2003; 75: 1455.
20. Davies DR, Bittmann I, Pardo J. Histopathology of calcineurin inhibitor-induced nephrotoxicity. Transplantation 2000; 69: SS11.
21. Remuzzi G, Perico N. Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int 1995; 52: S70.
22. Qi Z, Simanaitis M, Ekberg H. Malononitrilamides 715 and 279 prevent accelerated cardiac allograft rejection synergistically with cyclosporin A in presensitized rats. Transpl Immunol 1998; 6: 94.
23. Schorlemmer HU, Ruuth E, Kurrle R. Malononitrilamides synergistically prevent acute and treat ongoing skin allograft rejection with cyclosporine. Transpl Int 1998; 11: S340.
24. Jin MB, Nakayama M, Ogata T, et al. A novel leflunomide derivative, FK778, for immunosuppression after kidney transplantation in dogs. Surgery 2002; 132: 72.
25. Kyles AE, Gregory CR, Griffey SM, et al. Immunosuppression with a combination of the leflunomide analog, FK778, and microemulsified cyclosporine for renal transplantation in mongrel dogs. Transplantation 2003; 75: 1128.
26. Hamar P, Szabo A, Muller V, Heemann U. The involvement of activated T cells and growth-factor production in the early and late phase of chronic kidney allograft nephropathy in rats. Transpl Int 2002; 15: 446.
27. Birsan T, Dambrin C, Klupp J, et al. Effects of the malononitrilamide FK778 on immune functions in vitro in whole blood from non-human primates and healthy human volunteers. Transpl Immunol 2003; 11: 163.
28. Abboud HE. Platelet-derived growth factor and mesangial cells. Kidney Int 1992; 41: 581.
29. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286.
30. Shihab FS, Andoh TF, Tanner AM, et al. Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy. Kidney Int 1996; 49: 1141.
31. Hutchinson IV. The role of transforming growth factor-beta in transplant rejection. Transplant Proc 1999; 31: 9S.
32. Yao HW, Li J, Chen JQ, Xu SY. Inhibitory effect of leflunomide on hepatic fibrosis induced by CCl4 in rats. Acta Pharmacol Sin 2004; 25: 915.
33. Shawver LK, Schwartz DP, Mann E, et al. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin Cancer Res 1997; 3: 1167.
34. Xu X, Shen J, Mall JW, et al. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action. Biochem Pharmacol 1999; 58: 1405.
35. Lutz J, Risch K, Liu S, et al. Angiotensin type 1 and type 2 receptor blockade in chronic allograft nephropathy. Kidney Int 2006; 70: 1080.
36. Orth SR, Odoni G, Amann K, et al. The ET(A) receptor blocker LU 135252 prevents chronic transplant nephropathy in the "Fisher to Lewis" model. J Am Soc Nephrol 1999; 10: 387.
37. Lutz J, Zou H, Liu S, et al. Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation 2003; 76: 508.
38. Wang M, Liu S, Ouyang N, et al. Protective effects of FTY720 on chronic allograft nephropathy by reducing late lymphocytic infiltration. Kidney Int 2004; 66: 1248.